Statin Use and Risk of Community-Acquired Staphylococcus aureus Bacteremia : A Population-Based Case-Control Study
Copyright © 2017 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved..
OBJECTIVE: To ascertain whether persons treated with statins experience a decreased risk of community-acquired Staphylococcus aureus bacteremia (CA-SAB) as compared with nonusers.
PATIENTS AND METHODS: Using population-based medical registries, we conducted a case-control study including all adults with first-time CA-SAB and population controls matched on age, sex, and residence in Northern Denmark from January 1, 2000, through December 31, 2011. Statin users were categorized as current users (new or long-term use), former users, and nonusers. We used conditional logistic regression to compute odds ratios (ORs) for CA-SAB according to statin exposure, overall and stratified by intensity (<20, 20-39, ≥40 mg/d) and duration of use (<365, 365-1094, ≥1095 days).
RESULTS: We identified 2638 patients with first-time CA-SAB and 26,379 matched population controls. Compared with nonusers, current statin users experienced markedly decreased risk of CA-SAB (adjusted OR, 0.73; 95% CI, 0.63-0.84). The adjusted OR was 0.96 (95% CI, 0.60-1.51) for new users, 0.71 (95% CI, 0.62-0.82) for long-term users, and 1.12 (95% CI, 0.94-1.32) for former users as compared with nonusers. The CA-SAB risk decreased with increasing intensity of statin use; thus, compared with nonusers, the adjusted OR was 0.84 (95% CI, 0.68-1.04) for current users with daily dosages of less than 20 mg/d, 0.71 (95% CI, 0.58-0.87) for 20 to 39 mg/d, and 0.63 (95% CI, 0.49-0.81) for 40 mg/d or more. Conversely, we observed no differences in the risk of CA-SAB with successive increases in the duration of statin use.
CONCLUSION: Statin use was associated with a decreased risk of CA-SAB, particularly in long-term users.
| Errataetall: |
CommentIn: Mayo Clin Proc. 2017 Oct;92(10):1463-1465. - PMID 28982482 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:92 |
|---|---|
| Enthalten in: |
Mayo Clinic proceedings - 92(2017), 10 vom: 25. Okt., Seite 1469-1478 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Smit, Jesper [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Hydroxymethylglutaryl-CoA Reductase Inhibitors |
|---|
| Anmerkungen: |
Date Completed 24.10.2017 Date Revised 11.10.2018 published: Print CommentIn: Mayo Clin Proc. 2017 Oct;92(10):1463-1465. - PMID 28982482 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.mayocp.2017.07.008 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM276519299 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM276519299 | ||
| 003 | DE-627 | ||
| 005 | 20231225012206.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.mayocp.2017.07.008 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0921.xml |
| 035 | |a (DE-627)NLM276519299 | ||
| 035 | |a (NLM)28982483 | ||
| 035 | |a (PII)S0025-6196(17)30566-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Smit, Jesper |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Statin Use and Risk of Community-Acquired Staphylococcus aureus Bacteremia |b A Population-Based Case-Control Study |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.10.2017 | ||
| 500 | |a Date Revised 11.10.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Mayo Clin Proc. 2017 Oct;92(10):1463-1465. - PMID 28982482 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2017 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a OBJECTIVE: To ascertain whether persons treated with statins experience a decreased risk of community-acquired Staphylococcus aureus bacteremia (CA-SAB) as compared with nonusers | ||
| 520 | |a PATIENTS AND METHODS: Using population-based medical registries, we conducted a case-control study including all adults with first-time CA-SAB and population controls matched on age, sex, and residence in Northern Denmark from January 1, 2000, through December 31, 2011. Statin users were categorized as current users (new or long-term use), former users, and nonusers. We used conditional logistic regression to compute odds ratios (ORs) for CA-SAB according to statin exposure, overall and stratified by intensity (<20, 20-39, ≥40 mg/d) and duration of use (<365, 365-1094, ≥1095 days) | ||
| 520 | |a RESULTS: We identified 2638 patients with first-time CA-SAB and 26,379 matched population controls. Compared with nonusers, current statin users experienced markedly decreased risk of CA-SAB (adjusted OR, 0.73; 95% CI, 0.63-0.84). The adjusted OR was 0.96 (95% CI, 0.60-1.51) for new users, 0.71 (95% CI, 0.62-0.82) for long-term users, and 1.12 (95% CI, 0.94-1.32) for former users as compared with nonusers. The CA-SAB risk decreased with increasing intensity of statin use; thus, compared with nonusers, the adjusted OR was 0.84 (95% CI, 0.68-1.04) for current users with daily dosages of less than 20 mg/d, 0.71 (95% CI, 0.58-0.87) for 20 to 39 mg/d, and 0.63 (95% CI, 0.49-0.81) for 40 mg/d or more. Conversely, we observed no differences in the risk of CA-SAB with successive increases in the duration of statin use | ||
| 520 | |a CONCLUSION: Statin use was associated with a decreased risk of CA-SAB, particularly in long-term users | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Hydroxymethylglutaryl-CoA Reductase Inhibitors |2 NLM | |
| 700 | 1 | |a López-Cortés, Luis Eduardo |e verfasserin |4 aut | |
| 700 | 1 | |a Thomsen, Reimar W |e verfasserin |4 aut | |
| 700 | 1 | |a Schønheyder, Henrik C |e verfasserin |4 aut | |
| 700 | 1 | |a Nielsen, Henrik |e verfasserin |4 aut | |
| 700 | 1 | |a Frøslev, Trine |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Bãno, Jesús |e verfasserin |4 aut | |
| 700 | 1 | |a Søgaard, Mette |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Mayo Clinic proceedings |d 1964 |g 92(2017), 10 vom: 25. Okt., Seite 1469-1478 |w (DE-627)NLM000074527 |x 1942-5546 |7 nnns |
| 773 | 1 | 8 | |g volume:92 |g year:2017 |g number:10 |g day:25 |g month:10 |g pages:1469-1478 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.mayocp.2017.07.008 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 92 |j 2017 |e 10 |b 25 |c 10 |h 1469-1478 | ||